 |
市场调查报告书
商品编码
1907925
夜尿症市场：依药物类别、给药途径、剂型、作用机转、处方药类型、年龄层、性别、通路、最终用户及地区划分Nocturia Market, By Drug Class, By Route of Administration, By Dosage Form, By Mechanism of Action, By Prescription Type, By Age Group, By Gender, By Distribution Channel, By End User, By Geography |
||||||
价格
简介目录
夜尿症市场预计在 2025 年达到 44.1 亿美元，预计到 2032 年将达到 76.1 亿美元，2025 年至 2032 年的复合年增长率为 8.1%。
| 分析范围 | 分析详情 | ||
|---|---|---|---|
| 基准年 | 2024 | 市场规模（2025 年） | 44.1亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期（2025-2032 年）复合年增长率 | 8.10% | 预计金额（2032 年） | 76.1亿美元 |
全球夜尿症市场在更广泛的泌尿系统和睡眠障碍药物市场中占据重要地位，它针对的是一种常见的疾病，其特征是夜间需要醒来排尿。夜尿症影响着全球数百万人，其盛行率随着年龄的增长而显着增加，并影响着各个年龄层的男性和女性。
这种疾病不仅会扰乱睡眠模式，还会对生活品质产生显着影响，导致老年人白天疲劳、工作效率下降，并增加跌倒风险。市面上的治疗方法多种多样，包括药物疗法（如去氨加压素、抗胆碱能药物和α阻断剂）以及非药物疗法（如行为矫正和医疗设备） 。医疗专业人员越来越认识到，夜尿症是一种需要针对性治疗性介入的独立疾病，而不仅仅是潜在疾病的症状。病患和医疗专业人员对现有治疗方案的认识不断提高，加上全球人口老化以及糖尿病、心臟衰竭和良性前列腺增生等相关合併症盛行率的上升，这些因素都在持续推动市场扩张和治疗方案的创新。
市场动态
全球夜尿症市场主要受多种强劲因素驱动，这些因素共同创造了市场强劲成长和扩张的机会。其中最重要的驱动因素是全球人口的快速老化。夜尿症的盛行率老龄化显着增加，65岁以上族群的盛行率高达80%，扩大了需要治疗性介入的患者族群。医疗专业人员和患者对夜尿症的认识不断提高，他们逐渐意识到夜尿症是一种可治疗的疾病，而非老龄化的必然组成部分，这促使诊断率提高，患者就医意愿增强。此外，糖尿病、心血管疾病和良性前列腺增生等潜在疾病的盛行率不断上升，这些疾病都会导致夜间尿症的发生，进一步扩大了潜在患者族群。
然而，市场也面临许多製约因素。患者认知不足导致诊断和治疗延误，许多患者将其视为老龄化的正常现象，并未寻求医疗干预。新药认证的监管挑战，特别是考虑到夜尿症病因复杂且需要全面的安全性评估，可能会延缓创新治疗方法的上市。高昂的治疗费用和某些治疗方法的医疗覆盖范围有限，也可能阻碍患者获得最佳治疗。儘管有这些挑战，市场也蕴藏着巨大的机会，例如诊断工具的技术进步，使得患者分型更加精准，治疗方案更加个人化。新型治疗标靶和联合治疗的开发具有巨大的成长潜力，新兴市场不断完善的医疗基础设施将为全球扩张的市场参与企业带来新的收入来源。
本报告的主要特点
- 本报告对全球夜尿症市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和復合年增长率。
- 它还重点介绍了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
- 它还提供了有关市场驱动因素、限制因素和机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的关键见解。
- 全球夜尿症市场的主要企业将根据以下参数进行分析，例如公司概况、产品系列、主要亮点、财务表现和策略。
- 本报告提供的见解将使负责人和企业经营团队能够就未来的产品发布、合作关係、市场扩张和行销策略做出明智的决策。
- 《全球夜尿症市场》报告面向该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员可以透过分析全球夜尿症市场的各种策略矩阵来更轻鬆地做出决策。
目录
第一章 分析目标和先决条件
- 分析目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章：市场动态、监管与趋势分析
- 市场动态
- 司机
- 抑制因素
- 机会
- 影响分析
- 重大进展
- 监管情景
- 产品发布/核准
- PEST分析
- 波特五力分析
- 企业合併情景
- 产业趋势
4. 全球夜尿症市场按药物类别划分（2020-2032 年）
- 抗利尿剂（例如，加压素类似物，如去氨加压素）
- α1肾上腺素受体拮抗剂（例如，Tamsulosin嗪、西洛多辛、特拉唑嗪）
- 促效剂（例如奥昔布宁、托特罗定、索利那新、达非那新、曲司氯铵）
- β3肾上腺素促效剂（例如，Mirabegron、维贝隆）
- 袢利尿剂给药时间（例如，下午晚些时候服用Furosemide）
- 合併药物治疗（例如，Mirabegron+索利那新，α阻断剂+抗胆碱能药物）
5. 全球夜尿症市场依给药途径划分（2020-2032 年）
- 口服
- 鼻腔
- 舌下给药/口溶锭
- 肠外及其他全身给药途径
6. 全球夜尿症市场按剂型划分（2020-2032 年）
- 速释片剂和胶囊
- 缓释性/缓释口服剂型
- 口溶锭和薄膜
- 滴鼻剂/鼻腔液
- 注射
7. 全球夜尿症市场依作用机转划分（2020-2032 年）
- 血管加压素受体促效剂
- 平滑肌鬆弛剂
- 毒蕈碱受体阻断剂
- β3受体促效剂
- 靶向前列腺鬆弛剂
- 体液调节调变器
8. 全球夜尿症市场依处方药类型划分（2020-2032 年）
- 处方笺药（Rx）
- 非处方药
9. 全球夜尿症市场按年龄组别划分（2020-2032 年）
- 成人
- 老年人
第十章 全球夜尿症市场按性别划分（2020-2032 年）
- 男性
- 女士
第十一章 全球夜尿症市场依通路划分（2020-2032 年）
- 医院药房
- 零售药房
- 网路药房
第十二章 全球夜尿症市场（按最终用户划分）（2020-2032 年）
- 医院
- 泌尿系统诊所
- 长期照护机构及疗养院
- 居家医疗/自我照顾环境
第十三章 全球夜尿症市场区域分析（2020-2032 年）
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲国家
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 其他亚太地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
- 非洲
- 南非
- 北非
- 中非
第十四章 竞争格局
- Ferring Pharmaceuticals
- Astellas Pharma Inc.
- Pfizer Inc.
- AbbVie Inc.
- Merck &Co., Inc.
- Sanofi SA
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Ltd.
- Avadel Pharmaceuticals plc
- Sumitomo Pharma Co., Ltd.
- Urigen Pharmaceuticals Inc.
- Vantia Therapeutics Ltd.
- Viatris Inc.
- Allergan（an AbbVie company）
第十五章 分析师建议
- 机会
- 分析师观点
- Coherent Opportunity Map (COM)
第十六章 参考文献与分析方法
- 参考
- 分析方法
- 关于 Coherent Market Insights
简介目录
Product Code: CMI9058
Nocturia Market is estimated to be valued at USD 4.41 Bn in 2025 and is expected to reach USD 7.61 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.41 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.10% | 2032 Value Projection: | USD 7.61 Bn |
The global nocturia market represents a critical segment within the broader urological and sleep disorder therapeutics landscape, addressing a prevalent medical condition characterized by the need to wake up during the night to urinate. Nocturia affects millions of individuals worldwide, with prevalence rates increasing significantly with age, impacting both men and women across various demographic groups.
This condition not only disrupts sleep patterns but also substantially affects quality of life, leading to daytime fatigue, reduced productivity, and increased risk of falls among elderly populations. The market encompasses various treatment modalities including pharmacological interventions such as desmopressin, anticholinergics, and alpha-blockers, alongside non-pharmacological approaches including behavioral modifications and medical devices. Healthcare providers increasingly recognize nocturia as a distinct medical condition requiring targeted therapeutic intervention rather than merely a symptom of underlying disorders. The growing awareness among patients and healthcare professionals about available treatment options, coupled with an aging global population and rising prevalence of associated comorbidities such as diabetes, heart failure, and benign prostatic hyperplasia, continues to drive market expansion and innovation in therapeutic solutions.
Market Dynamics
The global nocturia market is primarily driven by several compelling factors that collectively contribute to robust market growth and expansion opportunities. The most significant driver is the rapidly aging global population, as nocturia prevalence increases substantially with age, affecting up to 80% of individuals over 65 years, creating an expanding patient base requiring therapeutic intervention. Rising awareness among healthcare providers and patients about nocturia as a treatable medical condition rather than an inevitable aspect of aging has led to increased diagnosis rates and treatment seeking behavior. Additionally, the growing prevalence of underlying conditions such as diabetes mellitus, cardiovascular diseases, and benign prostatic hyperplasia, which contribute to nocturia development, further expands the potential patient population.
However, the market faces notable restraints including limited awareness among patients leading to underdiagnosis and undertreatment, with many individuals accepting the condition as a normal part of aging without seeking medical intervention. Regulatory challenges for new drug approvals, particularly given the complex etiology of nocturia and the need for comprehensive safety profiles, can delay market entry of innovative treatments. High treatment costs and limited insurance coverage for certain therapeutic options may restrict patient access to optimal care. Despite these challenges, significant opportunities exist through technological advancement in diagnostic tools enabling better patient stratification and personalized treatment approaches. The development of novel therapeutic targets and combination therapies presents substantial growth potential, while expanding healthcare infrastructure in emerging markets offers new revenue streams for market participants seeking global expansion.
Key Features of the Study
- This report provides in-depth analysis of the global nocturia market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global nocturia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Ferring Pharmaceuticals, Astellas Pharma Inc., Pfizer Inc., AbbVie Inc., Merck & Co., Inc., Sanofi S.A., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Avadel Pharmaceuticals plc, Sumitomo Pharma Co., Ltd., Urigen Pharmaceuticals Inc., Vantia Therapeutics Ltd., Viatris Inc., Allergan (an AbbVie company).
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global nocturia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nocturia market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin)
- Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin)
- Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium)
- Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron)
- Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing)
- Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)
- Route Of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intranasal
- Sublingual/orodispersible
- Parenteral and other systemic routes
- Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Immediate-release tablets or capsules
- Modified/extended-release oral formulations
- Orodispersible tablets or film
- Nasal sprays or drops
- Injectable formulations
- Mechanism Of Action Insights (Revenue, USD Bn, 2020 - 2032)
- Vasopressin Receptor Agonists
- Smooth Muscle Relaxants
- Muscarinic Receptor Blockers
- Beta-3 Receptor Stimulants
- Prostate-Targeted Relaxants
- Fluid-Regulation Modulators
- Prescription Type Insights (Revenue, USD Bn, 2020 - 2032)
- Prescription-Only Medicines (Rx)
- Over-the-Counter Options (OTC)
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty urology clinics
- Long-term care and nursing facilities
- Home-care and self-administration settings
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Ferring Pharmaceuticals
- Astellas Pharma Inc.
- Pfizer Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Sanofi S.A.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Ltd.
- Avadel Pharmaceuticals plc
- Sumitomo Pharma Co., Ltd.
- Urigen Pharmaceuticals Inc.
- Vantia Therapeutics Ltd.
- Viatris Inc.
- Allergan (an AbbVie company)
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Nocturia Market, By Drug Class
- Global Nocturia Market, By Route of Administration
- Global Nocturia Market, By Dosage Form
- Global Nocturia Market, By Mechanism of Action
- Global Nocturia Market, By Prescription Type
- Global Nocturia Market, By Age Group
- Global Nocturia Market, By Gender
- Global Nocturia Market, By Distribution Channel
- Global Nocturia Market, By End User
- Global Nocturia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Nocturia Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Nocturia Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sublingual/orodispersible
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral and other systemic routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Nocturia Market, By Dosage Form, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Immediate-release tablets or capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Modified/extended-release oral formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Orodispersible tablets or film
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nasal sprays or drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injectable formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Nocturia Market, By Mechanism of Action, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Vasopressin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Smooth Muscle Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Muscarinic Receptor Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta-3 Receptor Stimulants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Prostate-Targeted Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Fluid-Regulation Modulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Nocturia Market, By Prescription Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prescription-Only Medicines (Rx)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Over-the-Counter Options (OTC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Nocturia Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Nocturia Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Nocturia Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Nocturia Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty urology clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Long-term care and nursing facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home-care and self-administration settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
13. Global Nocturia Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive Landscape
- Ferring Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Avadel Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumitomo Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Urigen Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vantia Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan (an AbbVie company)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
